Market Place
Sourcing Support
Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
31 Oct 2024 //
BUSINESSWIRE
Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024
09 Oct 2024 //
BUSINESSWIRE
Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
29 Jul 2024 //
BUSINESSWIRE
Verastem`s begins rolling sub of NDA to USFDA of avutometinib & defactinib combo
28 May 2024 //
PHARMABIZ
Verastem Nda Initiation: Avutometinib Defactinib Combo Rolling Submission
24 May 2024 //
BUSINESSWIRE
Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone
05 Mar 2024 //
BUSINESSWIRE
Verastem Oncology Outlines Key 2024 Strategic Priorities
29 Jan 2024 //
BUSINESSWIRE
Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib
13 Dec 2023 //
BUSINESSWIRE
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib
06 Nov 2023 //
BUSINESSWIRE
Verastem Presents Avutometinib and Defactinib Combination Program Updates
28 Sep 2023 //
BUSINESSWIRE
Verastem Oncology Announces Design for Trial of Avutometinib and Defactinib
05 Jul 2023 //
BUSINESSWIRE
Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Ovarian Cancer
30 Jun 2023 //
ONCLIVE
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial
26 Apr 2023 //
BUSINESSWIRE
Verastem Announces Data from PII RAMP-201 Trial of Avutometinib and Defactinib
24 Jan 2023 //
BUSINESSWIRE
Verastem Oncology Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Verastem Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib
06 Jun 2022 //
BUSINESSWIRE
Verastem Provides Financial Update to Support Development of VS-6766, Defactinib
28 Mar 2022 //
BUSINESSWIRE
Verastem Presents Updated PI/II Data of VS-6766 + Defactinib in Ovarian Cancer
19 Sep 2021 //
BUSINESSWIRE
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766
15 Dec 2020 //
BUSINESSWIRE
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766
30 Nov 2020 //
BUSINESSWIRE
Verastem Oncology Ph2 Registration-Directed Trial of VS-6766 and Defactinib
29 Nov 2020 //
BUSINESSWIRE
Verastem Oncology Announces of Preclinical Data Supporting the CombO of VS-6766
22 Jun 2020 //
BUSINESSWIRE
Verastem Announces Presentation of Preclinical Data VS-6766 and Defactinib
22 Jun 2020 //
BUSINESSWIRE
What`s in Store for Verastem (VSTM) This Earnings Season?
30 Oct 2018 //
NASDAQ
Verastem Oncology to Present Scientific Data Supporting Duvelisib & Defactinib
21 May 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.